NCT06804850View on ClinicalTrials.gov

Neoadjuvant Low-Dose Radiotherapy Plus Targeted-Immunotherapy vs Targeted-Immunotherapy Monotherapy in Resectable HNSCC: A Randomized Trial

PHASE2RecruitingINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

January 20, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Head and Neck Cancer
Interventions
DRUG

Tislelizumab

200mg IV Q3W

DRUG

Afatinib

30mg PO QD

RADIATION

Low dose radiotherapy

4Gy / 2f. Intensity-modulated radiotherapy was used for radiotherapy.

Trial Locations (1)

610000

RECRUITING

West China Hospital, Sichuan University, Chengdu

All Listed Sponsors
lead

West China Hospital

OTHER